Nina Skorytchenko

Nina is the co-founder and CEO of Avenna Ltd. Her mission is to make healthcare for chronic inflammatory disease (CIDs) more preventive and personalised. By developing more effective, affordable, and accessible precision medicine solutions we can enable early detection and treatment personalisation for variety of CIDs. Nina has background in finance, business, and healthcare and worked in large multinational companies including Nomura, Bloomberg and Schlumberger, as well as several entrepreneurship ventures.

Nina’s main ability and expertise is to connect the worlds of scientific research and business. She uses this experience to translate the most promising, research-grade technologies into practical solutions for individuals, clinicians, and biopharma. Nina works in collaboration with leading scientists, clinicians, and patients to translate R&D stage technologies into practical clinical solutions. This includes design and execution of clinical studies and trials, development of bioinformatics infrastructure to facilitate the translation of precision health programs for chronic disease prevention into clinical practice.